REFERENCES
- Amorim ML, Cabeda JM, Seca R, Mendes AC, Castro AP, Amorim JM. CMV infection of Liver transpLant recipients: compari-son of antigenemia and moLecuLar bioLogy assays. Liver Trans-pLant; 11;1004-1007.
- Weinberg A, Hodges TN, Li S, Cai G, Zamora MR. Comparison ofPCR,Antigenemia Assay, and Rapid BLood CuLture for Detection and Prevention of CytomegaLovirus after Lung TranspLantation. JournaL of CLinicaL MicrobioLogy 2000;38;2:768–772
- Kaipoe JS, Kroes ACM, de Jong MD, Schinkei J, de Brouwer CS, Beersma MFC, CLaas ECJ. Validation of CLinicaL Application of CytomegaLovirus PLasma DNA Load Measurement and Defini-tion of Treatment Criteria by AnaLysis of CorreLation to Antigen Detection. JournaL of CLinicaL MicrobioLogy 2004;42;4:1498–1504.
- Deback C, FiLLet AM, Dhebin N, Barrou B, Varnous S, Najiouk Fah F, Bricaire F, Agut H. Monitoring of human cytomegaLovirus infection in immunsuppressed patients using reaktime PCR on whoEe Mood. JournaL of CLinicaLViroLogy 2007;40:173–179
- Garrigue I, Boucher S, Couzi L, Caumont A, Dromer C, Neau-Cransac M, et al WhoEe Mood reaktime quantitative PCR for cytomegaLovirus infection foLLow-u p in transpLants recipients. JournaL of CLinicaLViroLogy 2006;36:72–75.
- Liliery D, BaLdanti F, Gatti M, Rovida F, Dossena L, De Grazia S et al ClinicaRy-based determination of safe DNAemia cutoff LeveLs for preemtive therapy or human cytomegaLovirus infec-tions in solid organ and hematopoietic stem ceLL transpLant re-cipients. J Med ViroE 2004;73:412–418.
- Alain S., Mazeron M-C. CytomegaLovirus. In : Huraux JM, NicoLas JC, Agut H, Peigue-Lafeuilie H et al Traité de viroLogie médi-caLe ; Paris :Estem.2003 :195–212.